CureVac Shareholders Transition to BioNTech Following Acquisition Completion

The publicly traded chapter for CureVac has officially closed. The German biopharmaceutical company is no longer listed on the Nasdaq, following the finalization of its acquisition by compatriot BioNTech SE. The transaction was completed on January 6, 2026, integrating CureVac's operations fully into the BioNTech corporate structure.

BioNTech now holds complete ownership of CureVac. The acquisition, structured as a post-offer reorganization, was valued at approximately $1.25 billion prior to completion. This strategic move was designed to merge CureVac's mRNA technology platform and intellectual property with BioNTech's established development and commercial infrastructure.

With the deal closed, CureVac shares were delisted from the exchange at the end of January. Former CureVac investors who participated in the exchange offer received BioNTech American Depositary Shares (ADS, ticker: BNTX) in return for their holdings. Consequently, investment themes that previously drove CureVac's valuation—such as updates from its oncology pipeline or outcomes from patent proceedings—are now embedded within the broader BioNTech equity story.

A Consolidated German mRNA Powerhouse

This integration creates a unified German biotechnology entity focused on mRNA research and development. The merger also resolves longstanding legal and competitive tensions between the two firms, headquartered in Tübingen and Mainz, respectively.

Should investors sell immediately? Or is it worth buying CureVac?

BioNTech gains control over CureVac's patent portfolio and its Tübingen production facility. Industry observers note this consolidation is poised to strengthen the combined entity's competitive stance against global rivals like Moderna, particularly in the fields of cancer vaccines and novel infectious disease treatments.

Strategic Focus and Investor Outlook

For the remainder of 2026, the focus shifts to the operational integration of the two companies. BioNTech's management has stated that the acquisition aims to bolster its oncology pipeline, leveraging CureVac's advances in shared-antigen cancer vaccines.

For existing shareholders, the investment landscape has shifted. Those who previously held positions in CureVac now have exposure to BioNTech's larger and more diversified corporate narrative. The central date for the transaction remains January 6, 2026, marking the point when CureVac ceased to have public shareholders and its market listing was terminated.